US FDA Should Regulate Ads Soliciting Mass Tort Suits, Group Says

Citing deaths and injuries caused when people stopped talking Xarelto in response to advertisements, US Chamber Institute for Legal Reform recommends Congress give FDA authority to halt misleading lawsuit ads.

A tort reform group wants the US FDA to regulate advertisements soliciting plaintiffs for Rx drug and medical device product liability suits, just as it does for manufacturer advertising.

A report commissioned by the U.S. Chamber Institute for Legal Reform recommends that Congress give the agency the authority to monitor lawsuit ads for misleading, scientifically unsupported, or false information...

More from US FDA

More from Agency Leadership